Phase 1/2 Study of Ocaratuzumab, an Fc-Engineered Humanized Anti-CD20 Monoclonal Antibody, in Low-Affinity FcγRIIIa Patients with Previously Treated Follicular Lymphoma-Reference-Cited by-同舟云学术

Phase 1/2 Study of Ocaratuzumab, an Fc-Engineered Humanized Anti-CD20 Monoclonal Antibody, in Low-Affinity FcγRIIIa Patients with Previously Treated Follicular Lymphoma

Published:2014-07-14 Issue:1 Volume:56 Page:42-48
ISSN:1042-8194
Container-title:Leukemia & Lymphoma
language:en
Short-container-title:Leukemia & Lymphoma

Author:

Ganjoo Kristen N.,de Vos Sven,Pohlman Brad L.,Flinn Ian W.,Forero-Torres Andres,Enas Nathan H.,Cronier Damien M.,Dang Nam H.,Foon Kenneth A.,Carpenter Susan P.,Slapak Christopher A.,Link Brian K.,Smith Mitchell R.,Mapara Markus Y.,Wooldridge James E.

Publisher

Informa UK Limited

Subject

Cancer Research,Oncology,Hematology

Link

http://www.tandfonline.com/doi/pdf/10.3109/10428194.2014.911859

Reference25 articles.

1. The future of anti-CD20 monoclonal antibodies: are we making progress?

2. Immunoglobulin G Fragment C Receptor Polymorphisms and Clinical Efficacy of Trastuzumab-Based Therapy in Patients With HER-2/neu–Positive Metastatic Breast Cancer

3. Impact of FcγRIIa-FcγRIIIa Polymorphisms and KRAS Mutations on the Clinical Outcome of Patients With Metastatic Colorectal Cancer Treated With Cetuximab Plus Irinotecan

4. Inhibitory Fc receptors modulate in vivo cytoxicity against tumor targets

5. FcγRIIIa-158V/F Polymorphism Influences the Binding of IgG by Natural Killer Cell FcγRIIIa, Independently of the FcγRIIIa-48L/R/H Phenotype

Cited by 27 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. A Review of Anti-CD20 Antibodies in the Management of B-Cell Lymphomas;Lymphatics;2024-01-05

2. Therapeutic antibodies against cancer—A step toward the treatment;Resistance to Anti-Cd20 Antibodies and Approaches for their Reversal;2024

3. Immunotherapy in hematologic malignancies: achievements, challenges and future prospects;Signal Transduction and Targeted Therapy;2023-08-18

4. Relevance of Fc Gamma Receptor Polymorphisms in Cancer Therapy With Monoclonal Antibodies;Frontiers in Oncology;2022-06-24

5. Pharmacogenomics Testing in Phase I Oncology Clinical Trials: Constructive Criticism Is Warranted;Cancers;2022-02-23